鲁抗医药 (600789.SH) Latest Company News

Aug 19, 2026, 08:38 UTC
Lukang Pharmaceutical's controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received approval from the National Medical Products Administration to become the marketing authorization holder of Crisaborole Ointment, transferring the holder from Zhejiang Saimei Pharmaceutical Co., Ltd. to Saite.
Source:
- finance.sina.cn
Aug 7, 2026, 10:29 UTC
Lukang Pharmaceutical received drug registration certificates from the National Medical Products Administration for dapagliflozin and metformin extended-release tablets (I) and (III), a combination product indicated for adults with type 2 diabetes.
Source:
- finance.sina.cn
Aug 7, 2026, 10:29 UTC
Lukang Pharmaceutical received a drug registration certificate from the National Medical Products Administration for Lenvatinib Mesylate capsules, specification 4mg, registration classification chemical drug category 4, indicated for patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 7, 2026, 10:29 UTC
Lukang Pharmaceutical received a drug registration certificate from the National Medical Products Administration for brexpiprazole tablets in strengths of 2mg, 1mg, and 0.25mg.
Source:
- finance.sina.cn
Aug 7, 2026, 09:39 UTC
Lukang Pharmaceutical's controlling subsidiary Saite Company received the supplementary application approval notice for Amikacin Sulfate Injection from the National Medical Products Administration on August 7, 2026.
Source:
- finance.sina.cn
Aug 5, 2026, 09:27 UTC
Lukang Pharmaceutical's wholly-owned subsidiary Shandong Lukang Bio-Manufacturing Co., Ltd. announced an investment of 370 million yuan to build a green bio-manufacturing project, which has been approved by the board of directors, with a construction period of about 18 months.
Source:
- finance.sina.cn
Aug 3, 2026, 09:13 UTC
Lukang Pharmaceutical's vancomycin hydrochloride for injection (0.5g) is provisionally selected in the 12th national centralized drug procurement, with the procurement period running until December 31, 2029.
Source:
- finance.sina.cn
Jul 2, 2026, 09:05 UTC
Lukang Pharmaceutical's subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received a Drug Registration Certificate for Rosuvastatin Ezetimibe Tablets (I) from the National Medical Products Administration.
Source:
- finance.sina.cn

600789.SH

Lukang Pharmaceutical received drug registration certificates from the National Medical Products Administration for dapagliflozin and metformin extended-release tablets (I) and (III), a combination product indicated for adults with type 2 diabetes.

Lukang Pharmaceutical received a drug registration certificate from the National Medical Products Administration for brexpiprazole tablets in strengths of 2mg, 1mg, and 0.25mg.

Lukang Pharmaceutical's controlling subsidiary Saite Company received the supplementary application approval notice for Amikacin Sulfate Injection from the National Medical Products Administration on August 7, 2026.

Lukang Pharmaceutical's wholly-owned subsidiary Shandong Lukang Bio-Manufacturing Co., Ltd. announced an investment of 370 million yuan to build a green bio-manufacturing project, which has been approved by the board of directors, with a construction period of about 18 months.

Lukang Pharmaceutical's vancomycin hydrochloride for injection (0.5g) is provisionally selected in the 12th national centralized drug procurement, with the procurement period running until December 31, 2029.

Lukang Pharmaceutical's subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received a Drug Registration Certificate for Rosuvastatin Ezetimibe Tablets (I) from the National Medical Products Administration.